Selected References:

• Bieńkowski CA, et al. 2022. Analysis of preventable risk factors for toxoplasma gondii infection in pregnant women: case-control study. Journal of Clinical Medicine 11(4):1005.
• Buzby, Jean C, 2001. “Children and Microbial Foodborne Illness,” Food Review/ National Food Review, United States Department of Agriculture, Economic Research Service, vol. 24(2), pages 1-6.
• Centers for Disease Control and Prevention (CDC), Listeria, 2021, https://www.cdc.gov/listeria/index.html.
• CDC, Bacterial Meningitis, 2021, https://www.cdc.gov/meningitis/bacterial.html
• CDC, Salmonella, 2022, https://www.cdc.gov/salmonella/.
• CDC, Toxoplasmosis, 2018, https://www.cdc.gov/parasites/toxoplasmosis/index.html.
• CDC, Vibrio, 2019, https://www.cdc.gov/vibrio/index.html
• Craig, AM, et al. 2019. Listeriosis in Pregnancy: A Review. Obstetrical & Gynecological Survey, 74(6), 362–368.
• Diaz-Herrara J. 2017. Listeriosis in pregnancy. Rev Med Hered 28(1):29-32
• Illinois Department of Public Health: Food Safety fact sheet, http://www.idph.state.il.us/public/hb/hbsafefood.htm
• Jeffs, E, et al. 2020. The epidemiology of listeriosis in pregnant women and children in New Zealand from 1997 to 2016: an observational study. BMC Public Health, 20.
• Moshfeghim M & Eftekhari MH. 2017. Toxoplasmosis in pregnancy, a rare clinical manifestation: a case report. Obstet Gynecol Cancer Res 2(1):e10091
• New York State Department of Health: Advice on Eating Game, 2014, https://www.health.ny.gov/environmental/outdoors/fish/health_advisories/advice_on_eating_game.htm
• Novotny L, et al. 2004. Fish: a potential source of bacterial pathogens for human beings. Vet. Med. 49(9):343-358
• Oyeyemi, Oyetunde T, et al. 2020. “Toxoplasmosis in Pregnancy: A Neglected Bane but a Serious Threat in Nigeria.” Parasitology 147(2):127–34.
• Quinlan J. 2013. Foodborne Illness Incidence Rates and Food Safety Risks for Populations of Low Socioeconomic Status and Minority Race/Ethnicity: A Review of the Literature. Int J Environ Res Public Health; 10(8): 3634-3652.
• United States Department of Agriculture (USDA). 2022. Food Safety and Inspection service, Safe Minimum Internal Temperature, https://www.fsis.usda.gov/wps/portal/fsis/topics/food-safety-education/get-answers/food-safety-fact-sheets/safe-food-handling/safe-minimum-internal-temperature-chart/ct_index.

Selected References:

• Aharon D. 1998. Pharmacology of leukotriene receptor antagonist. American Journal of Respirator Critical Care Medicine, 157; 214-219.
• American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI). 2000. The use of newer asthma and allergy medications during pregnancy. Ann Allergy Asthma Immunol, 84:475-480.
• Bakhireva LN, et al. 2007. Safety of leukotriene receptor antagonists in pregnancy. Journal of Allergy and Clinical Immunology, 119; 618-625.
• Cavero-Carbonell C, et al. 2017. Fetal exposure to montelukast and congenital anomalies: a population based study in Denmark. Birth Defects Res, 109(6):452-459.
• Datta P, et al. 2017. Transfer of montelukast into human milk during lactation. Breastfeed Med, 12:54-57. Hatakeyama S, et al. 2022. The safety of pranlukast and montelukast during the first trimester of pregnancy: a prospective, two-centered cohort study in Japan. Congenit Anom (Kyoto), 62(4):161-168.
• Merck Sharp y Dohme Corp. 2022. Etiquetado de productos Singulair. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c166755-7711-4df9-d689-8836a1a70885
• Nelsen LM et al. 2012. Congenital malformations among infants born to women receiving montelukast, inhaled corticosteroids, and other asthma medications. J Allergy Clin Immunol, 129(1):251-254.e1-6.
• Sarkar M, et al. 2009. Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes Eur J Clin Pharmacol, 65(12):1259-1264.

Selected References:

• Blotiere PO, et al. 2020. Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. BMJ Open 10(6).
• Brannon GE, Rolland PD. Anorgasmia in a patient with bipolar disorder type 1 treated with gabapentin. J Clin Psychopharmacol. 2000;20(3):379-81.
• Carrasco M, Rao SC, Bearer CF, Sundararajan S. Neonatal gabapentin withdrawal syndrome. Pediatr Neurol 2015;53:445-447
• Grant AC, Oh H. Gabapentin-induced anorgasmia in women. Am J Psychiatry. 2002;159(7):1247.
• Huybrechts KF, Bateman BT, Desai RJ, Hernandez-Diaz S, Rough K, Mogun H, Kerzner LS, Davis JM, Stover M, Bartels D, Cottral J, Patorno E. Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. Bmj. 2017;358:j3326. doi:10.1136/bmj.j3326.
• Johannessen SI, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia. 2005;46:775–7.
• Kaufman KR, Struck PJ. Gabapentin-induced sexual dysfunction. Epilepsy Behav. 2011;21(3):324-6.
• Kristensen JH, Ilett KF, Hackett LP, et al. Gabapentin and breastfeeding: A case report. J Hum Lact. 2006;22:426–8.
• Linnebank M, et al. 2011. Antiepileptic drugs interact with folate and vitamin B12 serum levels. Ann Neurol; 69(2):352-9.
• Loudin, S, et al. (2017). An Atypical Withdrawal Syndrome in Neonates Prenatally Exposed to Gabapentin and Opioids. Clinical and Laboratory Observations. Volume 181, P286-288.
• Ohman I, Vitols S, Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: Does a fetal accumulation occur during pregnancy? Epilepsia. 2005;46:1621–4.
• Ohman I, Tomson T. Gabapentin kinetics during delivery, in the neonatal period, and during lactation. Epilepsia 2009;50 (Suppl. 10):108. Abstract.
• Patorno E, et al. 2020. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLoS Med. 17(9):e1003322.

Selected References:

• Almgren M, et al. 2009. Population-based study of antiepileptic drug exposure in utero–influence on head circumference in newborns. Seizure, 18(10):672-5.
• Arfman IJ, et al. 2020. Therapeutic drug monitoring of antiepileptic drugs in women with epilepsy before, during, and after pregnancy. Clin Pharmacokinet, 59(4):427-445.
• Asranna A, et al. 2018. Do anti-epileptic drug modifications after first trimester of pregnancy influence fetal malformation or cognitive outcome? Epilepsy Research, 146: 121-125.
• Ban L, et al. 2015. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. PLoS One, 10(7): e0131130.
• Bech LF, et al. 2018. In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring. Journal of Neurology, Neurosurgery & Psychiatry, 89(12): 1324-1331.
• Birnbaum AK, et al. 2020. Antiepileptic drug exposure in infants of breastfeeding mothers with epilepsy. JAMA Neurology, 77(4): 441-450.
• Bjork MH, et al. 2022. Association of prenatal exposure to antiseizure medication with low risk of autism and intellectual disability. JAMA Neurology, 79(7)672-681.
• Blotière PO, et al. 2019. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology, 93(2):e167-e180.
• Borthen I. 2015. Obstetrical complications in women with epilepsy. Seizure, 28: 32-34.
• Bromley RL, et al. 2013. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery & Psychiatry, 84(6): 637-643.
• Bromley RL, et al. 2018. Fetal antiepileptic drug exposure and cognitive outcomes. Seizure, 44:225–231.
• Bromley R, et al. 2022. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database of Systematic Reviews, 8(8):CD010224.
• Bromley RL, et al. 2023. Neurodevelopment of babies born to mothers with epilepsy: a prospective observational cohort study. Epilepsia, 64:2454-2471.
• Clark CT, Wisner KL. 2018. Treatment of Peripartum Bipolar Disorder. Obstet Gynecol Clin North Am, 45(3):403-417.
• Cohen‐Israel M, et al. 2018. Short‐and long‐term complications of in utero exposure to lamotrigine. British Journal of Clinical Pharmacology, 84(1): 189-194.
• Cohen JM, et al. 2019. Anticonvulsant mood stabilizer and lithium use and risk of adverse pregnancy outcomes. J Clin Psych, 80(4):18m12572.
• Cohen JM, et al. 2023. Comparative safety of antiseizure medication monotherapy for major malformations. Ann Neurol, 93:551-562.
• Coste J, et al. 2020. Risk of neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. Scientific Reports, 10(1):17362.
• Cummings C, et al. 2011. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood, 96(7):643-647.
• Deshmukh U, et al. 2016. Behavioral outcomes in children exposed prenatally to lamotrigine, valproate, or carbamazepine. Neurotoxicol Teratol, 54:5-14.
• Diav-Citrin O, et al. 2017. Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Res 1,09:1196-1203.
• Dolk H, et al. 2008. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology, 71:714-722.
• Dolk H, et al. 2016. Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies. Neurology, 86(18):1716-1725.
• Dreier JW, et al. 2023. Prenatal exposure to antiseizure medication and incidence of childhood- and adolescence-onset psychiatric disorders. JAMA Neurology, 80(6):568-577.
• Dudukina E, et al. 2023. Prenatal exposure to pregabalin, birth outcomes and neurodevelopment – a population-based study in four Nordic countries. Drug Safety, 46;661-675.
• Fantaneau TA, et al. 2023. Real-world practices for the care of women with epilepsy during pregnancy: a Canadian perspective. Epilepsy and Behavior, 148:109468.
• Gerard EE, et al. 2015. An update on maternal use of antiepileptic medications in pregnancy and neurodevelopment outcomes. Journal of Pediatric Genetics, 4(2):94-110.
• Gómez-Ramiro M, et al. 2019. Adverse outcomes during pregnancy and major congenital malformations in infants of patients with bipolar and schizoaffective disorders treated with antiepileptic drugs: a systematic review. Psychiatr Pol, 53(2):223-244.
• Harden CL, et al. 2009. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology, 73:142–149.
• Hernandez-Diaz S, et al. 2017. Fetal growth and premature delivery in pregnant women on antiepileptic drugs. Ann Neurol, 82(3):457-465.
• Herzog AG, 2008. Disorders of reproduction in patients with epilepsy: primary neurological mechanisms. Seizure, 17(2):101-110.
• Hoeltzenbein M, et al. 2024. Antiepileptic treatment with levetiracetam during the first trimester and pregnancy outcome: an observational study. Epilepsia, 65(1):26-36.
• Holmes LB, et al. 2011. Fetal effects of anticonvulsant polytherapies. Arch Neurol, 68(10):1275-1281.
• Huber-Mollema Y, et al. 2020. Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology, 267:1724-1736.
• Huber-Mollema Y, et al. 2019. Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy. Epilepsia, 60:1069-1082.
• Husebye ES, et al. 2018. Verbal abilities in children of mothers with epilepsy: association to maternal folate status. Neurology, 91:e811-21.
• Jazayeri D, et al. 2018. Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure, 56: 111-114.
• Kacirova I, et al. 2019. A short communication: lamotrigine levels in milk, mothers, and breastfed infants during the first postnatal month. Therapeutic Drug Monitoring, 41(3):401-404.
• Kacirova I, et al. 2022. Monitoring of lamotrigine concentrations in mothers, colostrum, and breastfed newborns during the early postpartum period. Biomedicine and Pharmacolotherapy, 151:113167.
• Khan SJ, et al. 2016. Bipolar disorder in pregnancy and postpartum: principles of management. Curr Psychiatry Rep, 18(2):13.
• Kohn E, et al. 2022. Magnitude of lamotrigine exposure through breastfeeding. Breastfeeding Medicine, 17(4):341-348.
• Kuczynska J, et al. 2019. Comparison of plasma, saliva, and hair lamotrigine concentrations. Clinical Biochemistry. 74:24-30.
• Leutritz AL, et al. 2022. Psychotropic medication in pregnancy and lactation and development of exposed children. Br J Clin Pharmacol, 89(2):737-750.
• Li Y, Meador KJ. 2022. Epilepsy and pregnancy. Continuum (Minneap Minn), 28(1):34-54.
• MacEachern DB, et al. 2019. Infertility, impaired fecundity, and live birth/pregnancy ratio in women with epilepsy in the USA: findings of the Epilepsy Birth Control Registry. Epilepsia, 60(9):1993-1998.
• McVearry KM, et al. 2009. A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy Behav, 16(4):609-616.
• Meador K, et al. 2011. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain, 134:396-404.
• Meador KJ, et al. 2014. Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. JAMA Pediatr, 168(8):729-736.
• Montouris G, et al. 2005. Reproductive and sexual dysfunction in men with epilepsy. Epilepsy & Behavior, 7:7-14.
• Mostacci B, et al. 2018. Emilia-Romagna study on pregnancy and exposure to antiepileptic drugs (ESPEA): a population-based study on prescription patterns, pregnancy outcomes and fetal health. J Neurol Neurosurg Psychiatry, 89:983–988.
• American College of Obstetricians and Gynecologists. 2017. Neural tube defects. Practice Bulletin No. 187. Obstet Gynecol 130(6):e279–e290.
• Newport DJ, et al. 2008. Lamotrigine in breast milk and nursing infants: determination of exposure. Pediatrics, 122(1):e223-231.
• Nordmo E, et al. 2009. Severe apnea in an infant exposed to lamotrigine in breast milk. Ann Pharmacother, 43:1893-1897.
• Ohman I, et al. 2000. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia, 41:709-713.
• Pariente G, et al. 2017. Pregnancy outcomes following in utero exposure to lamotrigine: a systematic review and meta-analysis. CNS Drugs, (6):439-450.
• Paulzen M, et al. 2015. Lamotrigine in pregnancy – therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood. Int Clin Psychopharmacol, 30(5):249-254.
• Pekoz MT, et al. Birth outcomes in pregnant women with epilepsy: A nationwide multicenter study from Türkiye. Epilepsia, 64:2310-2321.
• Prakash C, et al. 2016. Maternal and fetal outcomes after lamotrigine use in pregnancy: a retrospective analysis from an urban maternal mental health centre in New Zealand. Psychopharmacol Bull, 46(2):63-69.
• Razaz N, et al. 2017. Association between pregnancy and perinatal outcomes among women with epilepsy. JAMA Neurology, 74(8):983-991.
• Ren T, et al. 2023. Prenatal carbamazepine exposure and academic performance in adolescents: a population-based cohort study. Neurology, 100(7):e728-e738.
• Richards N, et al. 2019. Developmental outcomes at age four following maternal antiepileptic drug use. Epilepsy & Behavior, 93:73-79.
• Rihtman T, et al. 2013. Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: cognitive, motor, sensory and behavioral function. Reprod Toxicol, 41:115–125.
• Semet M, et al. 2017. The impact of drugs on male fertility: a review. Andrology, 5(4):640-663.
• Schmidt CT, et al. 2023. Transfer of anticonvulsants and lithium into amniotic fluid, umbilical cord blood & breast milk: a systematic review & combined analysis. Prog Neuropsychopharmacol Biol Psychiatry, 124:110733.
• Shi X, et al. 2022. Effects of antiepileptic drugs polytherapy on pregnancy outcomes in women with epilepsy: an observation study in northwest China. Epilepsy Behav, 135:108904.
• Thomas SV, et al. 2017. Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India. Epilepsia, 58:274–281.
• Thomas SV, et al. 2022. Differential impact of antenatal exposure to antiseizure medications on motor and mental development in infants of women with epilepsy. Discord, 24(3):531-540.
• Tomson T, et al. 2011. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol, 10(7):609-617.
• Tomson T, et al. 2018. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet neurol, 17(6):530-538.
• Tomson T, et al. 2019. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology, 93(9):e831-e840.
• Vajda FJ, et al. 2013. Lamotrigine in epilepsy, pregnancy and psychiatry–a drug for all seasons? Journal of Clinical Neuroscience. 20(1):13-16.
• Vajda FJ, et al. 2019. Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure, 65:6-11.
• Veiby G, et al. 2013. Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurol, 70:1367-1374.
• Veiby G, et al. 2015. Epilepsy and recommendations for breastfeeding. Seizure, 28:57-65.
• Velez-Ruiz NJ, et al. 2015. Neurodevelopmental effects of fetal antiepileptic drug exposure. Drug Safety, 38(3): 271-278.
• Veroniki AA, et al. 2017. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Medicine, 15(1):95.
• Vieta E, et al. Lamotrigine efficacy, safety, and tolerability for women of childbearing age with bipolar disorder: meta-analysis from four randomized, placebo-controlled maintenance studies. European Neuropsychopharmacology, 78:81-92.
• Wakil L, et al. 2009. Neonatal outcomes with the use of lamotrigine for bipolar disorder in pregnancy and breastfeeding: a case series and review of the literature. Psychopharmacol Bullb 42:91-98.
• Wiggs KK, et al. 2020. Antiseizure medication use during pregnancy and risk of ASD and ADHD in children. Neurology, 95;e3232-e3240.
• Yeh TC, et al. 2021. Bipolar women’s antepartum psychotropic exposure and offspring risk of attention-deficit/hyperactivity disorder and autism spectrum disorder. Journal of Affective Disorders, 295:1407-1414.

Selected References:

• Briggs GG, et al. 2017. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Eleventh Edition. Philadelphia, PA: Wolters Kluwer.
• Committee on Drugs, American Academy of Pediatrics. 2001. The transfer of drugs and other chemicals into human breast milk. Pediatrics. 108:776-789.
• Egerman, et al. 1992. The tetracyclines. Obstet Gynecol Clin NA. 19(3):551-561.
• Genot MT, et al. 1970. Effect of administration of tetracycline on teeth. J Oral Med. 25:75-79.
• Gilman AG, et al. (Eds). 1985. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Seventh Edition. Macmillan, New York.
• Kline, et al. 1964. Transplacental effect of tetracycline on teeth. JAMA. 188:178.
• Kutscher, et al. 1966. Discoloration of deciduous teeth induced by administration of tetracycline antepartum. Am J Obstet Gynecol. 96:291-292.
• Muanda FT, Sheehy O, Bérard A. 2017. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. Br J Clin Pharmacol. Nov;83(11):2557-2571.
• O’Rahilly R and Mueller F. 1992. Human Embryology & Teratology. New York: Wiley-Liss.
• The WHO Working Group, Bennet, PN (ed). 1988. Drugs and Human Lactation. New York: Elsevier.
• Vennila V, et al. 2014. Tetracycline-induced discoloration of deciduous teeth: case series. J Int Oral Health 6(3): 115-11